I contend that the 5.2 mo. Result (157 days) is good news – not bad news. It should be enough for approval (if replicated in Phase 3), given this combo’s superior tolerability vs. the alternatives. And its superior tolerability should make it a very popular drug for 3rd line patients and more. Comparing the 5.2 mo. result to the 11.8 mo. result is like comparing apples to orangutans, because of the 3 enormous differences shown above.
The fact that the Clive-only arm was not a true control group may have added to the market’s confusion.